Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide. We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.

Being awarded the AbbVie Scandinavia Golden Ticket is a tremendous honor and validation of our innovative approach to biotechnology. This recognition not only fuels our commitment to pushing the boundaries of biotech but also significantly accelerates our mission to meet the unmet medical needs of today. We are eager to leverage this opportunity to enhance patient treatment methods and improve quality of life.

The addition of Juan to our team represents a key milestone for AAX. His combination of technical know-how and forward-thinking leadership is set to elevate our technologies to new heights of innovation and market success. Juan's contribution is essential as we strive for scientific excellence and leadership in the bioanalytical market.

These appointments mark a significant milestone for AAX Biotech and are anticipated to play a vital role in the company’s growth and the development of our cutting-edge technologies, Seqitope™ and Opti-mAb™. We believe that the diverse expertise of our new board members will drive innovation and enhance our strategic initiatives in the evolving biotech landscape.

We are thrilled to join forces with Oblique Therapeutics and contribute our powerful Seqitope™ technology to their drug development efforts. Our high-resolution, high-throughput method will empower Oblique Therapeutics to expedite their development process and bring novel therapeutics to the market faster.

We are thrilled to have Maria join the team as we strengthen our IP portfolio and build partnerships with biotech and pharma companies. Maria’s combined experience in antibody research and business development will be instrumental for advancing AAX Biotech’s cutting-edge technologies for antibody therapeutics.